SCIENTIFIC POSTER

The Development of Next Generation Affinity Resins

Addressing the need for high capacity, improved stability, and innovative characteristics

Affinity products are increasingly challenged by the development of a wider array of mAb-based therapies requiring specialist purification strategies. Novel therapeutics including bispecific antibodies and Fc-fusion proteins often have unique challenges for both upstream and downstream processes. 

Download the scientific poster and view the comparisons study between three molecules: an IgG1 Fc-fusion protein (Fc-Fusion), an IgG4 monoclonal antibody (mAb), and an IgG1 bispecifi c antibody (BsAb).